What is Aclaris Therapeutics's change in deferred revenue?

Aclaris Therapeutics (ACRS) reported change in deferred revenue of -$854K in Q1 2026.

How has Aclaris Therapeutics's change in deferred revenue changed year-over-year?

Aclaris Therapeutics's change in deferred revenue decreased by 2.5% year-over-year, from -$833K to -$854K.

What does change in deferred revenue mean?

Change in payments received from customers for goods/services not yet delivered — a key SaaS and subscription metric.

Aclaris Therapeutics ACRS Change in Deferred Revenue

Change in Deferred Revenue at other companies

Kymera TherapeuticsKYMR

-$34.37M-1,536%

CytomX TherapeuticsCTMX

-$9.61M+78.5%

Protagonist TherapeuticsPTGX

-$3.27M+40.5%

Arcus BiosciencesRCUS

-$17M+39.3%

Alumis Inc.ALMS

$2.26M-13.5%

Janux TherapeuticsJANX

$46.27M—

Other financials

Income statement

See full

Revenue$2.0M+37.2%

Gross profit$1.6M+68.7%

Operating income-$22.2M-22.7%

Net income-$19.8M-31.4%

EPS (diluted)-$0.15-25.0%

Balance sheet

See full

Cash & equivalents$28.7M-5.6%

Total debt$2.0M-20.1%

Total equity$143.6M-0.3%

Total assets$198.7M+0.3%

Cash flow

See full

Operating cash flow-$18.1M-39.0%

CapEx$13.0K-69.8%

Free cash flow-$18.2M-38.6%

Valuation

See full

Market cap$685.75M+337%

Enterprise value$659.07M+410%

P/S82×+73.1×

Profitability

See full

Gross margin76.3%-9.7pp

Operating margin-961.9%+259pp

Net margin-832.6%+132pp

FCF margin-624.9%—

Returns & leverage

See full

Return on equity-48.4%-15.4pp

Debt / equity0×0.0×

Current ratio4×-1.0×

Where this comes from

Reported directly by Aclaris Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInContractWithCustomerLiability.

The official record: Aclaris Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Aclaris Therapeutics's change in deferred revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Aclaris Therapeutics's change in deferred revenue?: Aclaris Therapeutics (ACRS) reported change in deferred revenue of -$854K in Q1 2026.
How has Aclaris Therapeutics's change in deferred revenue changed year-over-year?: Aclaris Therapeutics's change in deferred revenue decreased by 2.5% year-over-year, from -$833K to -$854K.
What does change in deferred revenue mean?: Change in payments received from customers for goods/services not yet delivered — a key SaaS and subscription metric.